The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...

VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...

Prevnar revenues were in line with the Zacks ... The adjusted tax rate is expected to be approximately 15% in 2025. Pfizer’s fourth-quarter results were strong as it beat estimates for earnings ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

The Phase 2 infant study is a randomized, double-blind, active controlled trial, comparing VAX-31 to the existing Prevnar 20 (PCV20 ... with a booster at 12-15 months of age.

Prevnar 20, as I said was approved in March ... I think the vocabulary you used included a capacity of perhaps in the $10 billion to $15 billion ZIP code. And I'm curious to know what you're ...

Key pipeline assets include the CDK4 inhibitor, the SV and PD-L1 ADCs, and the next-generation Prevnar vaccine, all of which have the potential to be blockbuster products. Pfizer Inc. (NYSE ...

The 15-valent conjugate vaccine was at least as effective as Pfizer's 13-valent Prevnar 13 in the study, which involved infants up to 15 months old, and will form the basis of regulatory filing to ...

It covers 15 different pneumococcal serotypes – two more than Pfizer's current Prevnar 13 shot – and has been approved for use in patients aged 18 or over. Pfizer's updated 20-valent vaccine ...

This event will provide resources and information to help create a healthier and more productive farming environment.